Evidence map›Paper›PMID 42004225›Full record

ArticleGenes & diseases2026

Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer.

Marc C Pulanco, Xiang Yu Zheng, Alexander Sankin, Deyou Zheng, Xingxing Zang

Abstract read
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marc C PulancoDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, New York 10461, USA.
Xiang Yu ZhengMarilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders, Albert Einstein College of Medicine, New York 10461, USA.
Alexander SankinMarilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders, Albert Einstein College of Medicine, New York 10461, USA.
Deyou ZhengMarilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders, Albert Einstein College of Medicine, New York 10461, USA.
Xingxing ZangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, New York 10461, USA.

Funding

Tumor-expressed immune checkpoint B7x-mediated resistance to anti-CTLA-4 therapy.R01CA175495 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ZANG, XINGXING · 2014 to 2025
$5.1M
A New Immune Checkpoint Pathway in Human Bladder CancerR01CA262132 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Xingxing Zang · 2023 to 2026
$2.4M
Understanding mechanisms of immunoevasion by precancer stem cells for breast cancer interceptionR01CA306893 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Wenjun Guo, Xingxing Zang · 2026 to 2026
$680k
NCI NIH HHS R01 CA175495NCI NIH HHS R01 CA262132NCI NIH HHS R01 CA306893
6 · The paper itself

Abstract

Cancer cells adopt multiple strategies to avoid detection and destruction by the immune system, including exploiting immune checkpoint pathways. B7x (B7-H4, B7S1, or

Indexed as

B7x (B7-H4, B7S1, or VTCN1)Bladder cancerCancer immunotherapyCheckpoint inhibitorsImmune checkpointsImmune evasionResistance mechanismTumor microenvironment

Identifiers

PMID42004225
PMCPMC13089162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.